New CB2 agonists for the treatment of inflammatory bowel diseases—Development of an active drug candidate for oral administration
Description
CB2 receptor is highly expressed in immune system and intestinal epithelial cells.
This receptor plays an important role in inflammation.
Studies have shown that a particular selective CB2 receptor agonist reduces colon inflammation in models of colitis induced by mustard oil or by sodium dextran sulfate (DSS).
Many pharmaceutical companies consider the CB2 receptor as a therapeutic target of interest for the treatment of chronic inflammatory diseases or neurodegenerative diseases.
More information